Study of Low-Dose Bevacizumab with Standard Radiotherapy for Children and Teens with Diffuse Intrinsic Pontine Glioma DIPG Using MRI Perfusion to Guide Treatment Approach

What this Trial Is About

Researchers are investigating survival outcomes in children diagnosed with Diffuse Intrinsic Pontine Glioma DIPG, a serious brain tumor with limited treatment options. This study aims to see if using MRI perfusion imaging to classify tumors as hyperperfused or hypoperfused can guide treatment to improve survival. The trial is evaluating whether adding low-dose Bevacizumab to standard radiotherapy or using ultra-low-dose radiotherapy alone affects patient outcomes. Participants with hyperperfused tumors will receive weekly low-dose Bevacizumab alongside conventional radiotherapy over six weeks. Those with hypoperfused tumors will receive an ultra-low-dose radiotherapy regimen designed to match the biological effect of standard treatment but with altered dosing. Both groups follow specific treatment protocols based on MRI perfusion results, with no placebo or randomization involved. During the study, patients will undergo MRI assessments at diagnosis and regular monitoring for survival, disease progression, side effects, steroid use, relapse patterns, treatment adherence, and quality of life. Follow-up evaluations continue for up to 100 months or until disease progression or death. Researchers will primarily measure overall survival with a median target of 12 months from diagnosis to assess the impact of the treatment strategies.

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma